Seamless Early-Stage Clinical Drug Development (Phase 1 to 2a) for Novel therapeutic Agents for the Spectrum of Alzheimer’s Disease (AD) and AD-related Dementias (ADRD) (UG3/UH3 Clinical Trial Required)
Grant Overview
Application Deadline
November 19, 2026
Funding Organization or Agency
National Institutes of Health
Award or Funding Amount
Not specified
Apply for This Grant
Official Grant or Application Link
